Jones Financial Companies
ATNM icon

Jones Financial Companies’s Actinium Pharmaceuticals ATNM Stock Holding History

Jones Financial Companies’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$362 Hold
351
– – ﹤0.01% 4543
2025
Q4 		$477 Hold
351
– – ﹤0.01% 4170
2025
Q3 		$565 Buy
351
+51
+17% +$83 ﹤0.01% 4021
2025
Q2 		$426 Buy
+300
New +$449 ﹤0.01% 3825

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jones Financial Companies's ATNM Position: Q1 2026 in Review

Jones Financial Companies held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 351 shares worth $362. The position accounts for ﹤0.01% of the portfolio, ranked #4543.

Jones Financial Companies first reported a position in ATNM in Q2 2025 and has held it in 4 quarters since. The position peaked at $565 in Q3 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Jones Financial Companies held 351 shares of Actinium Pharmaceuticals worth $362 as of Q1 2026.
  • Jones Financial Companies left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4543 holding.
  • Jones Financial Companies first reported a position in Actinium Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Jones Financial Companies's Actinium Pharmaceuticals position peaked at $565 in Q3 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.